Prolonged Response to Anti–PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden by Gbolahan, Olumide et al.
Prolonged Response to Anti–PD-1 Antibody Therapy in Chemotherapy-Refractory 
Cholangiocarcinoma With High Tumor Mutational Burden 
Olumide Gbolahan MBBS a , Neda Hashemi-Sadraei MBBS b and Bert O’Neil MD c 
a. University of Alabama at Birmingham School of Medicine, Birmingham,
Alabama;
b. University of New Mexico School of Medicine, Albuquerque, New Mexico;
and
c. Indiana University School of Medicine, Indianapolis, Indiana.
ABSTRACT 
Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and 
overall survival is poor. Progress in the development of new therapeutic options for 
metastatic cholangiocarcinoma (CCA) has been slow; hence, to date, there are no 
approved second-line agents in this setting. Although the development of immune 
checkpoint inhibitors has significantly improved overall survival in a variety of 
malignancies, there has not been a clinically important impact in CCA. This report 
presents a 66-year-old patient with chemotherapy-refractory iCCA who experienced a 
prolonged response to immunotherapy. Tumor genome profiling revealed a high tumor 
mutation burden of 17 mutations per megabase in the absence of microsatellite instability. 
He was started on immunotherapy with nivolumab and has experienced an ongoing 
response for 16 months without clinical symptoms and only minimal radiologic disease. 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Gbolahan, O., Hashemi-Sadraei, N., & O’Neil, B. (2019). Prolonged Response to Anti–PD-1 Antibody Therapy in 
Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. Journal of the National 
Comprehensive Cancer Network, 17(6), 644–648. https://doi.org/10.6004/jnccn.2019.7304
 
 
Intrahepatic cholangiocarcinoma (iCCA) remains recalcitrant to treatment, with a 
median survival of only 26 to 30 months in localized and resectable disease.1,2 In the 
more common locally advanced/metastatic setting, outcomes are even more dire. A 
median overall survival of 11.7 months was reported with combination gemcitabine + 
cisplatin in the first-line setting.3 Despite this high mortality and reports of increasing 
incidence of iCCA,4 little progress has been made in the development of new therapeutic 
options. Indeed, there are no agents (single-therapy or combination) approved in the 
second line for advanced/metastatic iCCA, and in this era of precision medicine and 
immune therapy, there are no biologic agents used outside clinical trials. Preliminary 
results of the KEYNOTE-028 study (ClinicalTrials.gov Identifier: NCT02054806) showed 
no radiographic complete response among 24 patients with PD-L1–positive (>1% 
expression threshold) advanced biliary tree cancer treated with pembrolizumab. The 
overall response rate was 17%, and 5 patients remained on treatment for 40+ to 42+ 
weeks at the time of the report.5 
This report presents a patient with chemotherapy-refractory recurrent metastatic iCCA 
who has experienced a durable response to third-line anti–PD-1 immune checkpoint 
inhibitor (ICI) therapy for >12 months. Targeted genetic sequencing before treatment 
revealed an unusually high tumor mutational burden (TMB), and we posit that this is the 
reason for the prolonged response. 
CASE REPORT 
A 66-year-old white man with a history of type 2 diabetes mellitus presented to the 
emergency room after a near-syncopal event. He was noted to be jaundiced, and an 
ultrasound scan of the liver revealed a 2.4- × 2.0-cm hypoechoic mass in the central right 
hepatic lobe. This was confirmed by subsequent imaging with CT and MRI. No lymph 
node involvement or evidence of lesions suspicious for metastasis was evident within the 
abdomen or thorax. Cytology through fine-needle aspiration of the mass via an 
endoscopic ultrasound procedure showed moderately differentiated cholangiocarcinoma 
(CCA). The patient underwent exploratory laparotomy, and right hepatectomy, 
cholecystectomy, extrahepatic bile duct resection, and Roux-en-Y hepaticojejunostomy 
were performed in June 2015. Within the right hepatectomy specimen, there was a 3.3-
 
 
cm poorly differentiated CCA with involvement of the vascular (hepatic vein) margin. The 
mass was staged as poorly differentiated pT2N0 CCA (stage II) after R1 resection; CA 
19-9 level was not elevated (<37 U/mL). The patient received adjuvant chemoradiation 
with capecitabine and 50.4 Gy of radiation in 28 fractions. 
Three months after chemoradiation, CT revealed indeterminate subcentimeter pulmonary 
nodules. Repeat scan 3 months later showed a 2.2-cm left hepatic lobe mass. No 
pulmonary involvement was seen. Biopsy results of the lesion in the left hepatic lobe were 
consistent with metastatic CCA. At that point, the patient received 8 cycles of 
chemotherapy with gemcitabine + cisplatin. At the end of systemic therapy in July 2016, 
imaging revealed a partial response in the left hepatic lobe mass, which now measured 
1.6 cm, with no other lesions. A PET/CT scan obtained in August 2016 to assess residual 
tumor activity and rule out more widespread disease before planned local therapy for the 
liver disease confirmed the liver mass (2.3 cm; standardized uptake value [SUV], 14.7) 
and also showed a 1.6-cm hypermetabolic umbilical nodule (SUV, 11.4) and a 1.3-cm 
perirectal nodule (SUV, 11.7). The patient was started on systemic therapy with second-
line therapy with combination 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and received 
palliative stereotactic body radiation therapy to the liver and painful umbilical nodules. 
Upon further disease progression, he was referred to our phase I clinic. 
At his first visit to our clinic, he reported that FOLFOX had recently been stopped in 
December 2016 after 6 cycles due to clinical (worsening abdominal pain and ascites) and 
radiologic progression. He reported mild abdominal pain and fatigue, but his ECOG 
performance status was 1, with minimal adverse effects from the previous chemotherapy. 
The right hepatectomy tumor specimen was sent for panel-based tumor genomic profiling 
on the FoundationOne platform (Foundation Medicine),6 which revealed a KRAS(exon 4) 
A146T mutation and BRCA2 R3052Q mutation (Table 1). Results of PD-L1 staining were 
negative. Importantly, the testing also found a TMB of 17 mutations/Mb in the absence of 
microsatellite instability (MSI). On the basis of high TMB, the patient was started on anti–
PD-1 antibody therapy (nivolumab) in March 2017. Interval imaging 2 months after 
initiation of therapy showed a stable 1.5-cm left hepatic lobe nodule, a partial response in 
the perirectal lesion, and a complete response in previously described inguinal canal 
 
 
nodules. To date, the patient has had minimal residual disease since scans obtained 7 
months into treatment (Figure 1). His clinical symptoms (abdominal pain and ascites) 
have completely resolved, and he has continued to receive nivolumab with minimal 
adverse events except for grade 1 fatigue. 
Table 1. 
















Perirectal metastatic lesion (arrows) responding to nivolumab. (A) Perirectal PET-avid 
lesion measuring 2.3 cm at baseline. (B) Perirectal lesion measuring 1.7 cm 2 months 
after start of nivolumab. (C) Minimal residual perirectal lesion 7 months after start of 
nivolumab. 
DISCUSSION 
ICIs (immunotherapy) have transformed the management of a variety of advanced and 
metastatic solid tumors, particularly melanoma and non–small cell lung cancer (NSCLC). 
In addition to improving progression-free and overall survival, immune therapy has the 
potential to produce very prolonged responses and possibly even cures in patients with 
previously incurable cancer.7 However, the therapeutic benefit of immunotherapy has 
been inconsistent across the panoply of tumors for which it is used. A number of patients 
with melanoma or NSCLC have disappointing responses to immunotherapy. There is 
therefore an ongoing search for biomarkers that predict response to therapy. 
PD-L1 expression is the most widely studied biomarker of response to immune therapy 
and is the most commonly used metric. Higher expression of PD-L1 is associated with 
improved benefit from immune therapy in a number of cancer types.8 However, the 
limitations of PD-L1 expression as a predictor of response to immune therapy have been 
 
 
documented,9,10 especially given that responses are also seen in “PD-L1–negative 
tumors” across tumor types. 
Mismatch repair (MMR) deficiency (often defined by MSI) is caused by loss or 
methylation-based suppression of the genes that encode MMR proteins 
(MLH1, MSH2, MSH6, PMS2, and EpCAM). MMR deficiency is another established 
predictive marker for response to immune therapy. In a pivotal phase II study 
(ClinicalTrials.gov identifier: NCT01876511), treatment with pembrolizumab was 
associated with a response rate of 53% in MMR-deficient tumors (colorectal and 
noncolorectal cancers) compared with 0% for MMR-proficient tumors.11 MMR deficiency 
leads to a significant increase in mutation frequency and consequently a higher 
neoantigen burden of the tumor. This increase in neoantigen quantity and diversity is 
thought to stimulate an improved immune response to the tumor.12 In the absence of 
MMR deficiency, an increase in TMB also seems to be an independent and bona fide 
predictive biomarker of response to ICI therapy.13 For example, in melanoma, Snyder et 
al14 showed that presence of >100 nonsynonymous mutations per exome was associated 
with an improved response rate and survival in response to anti–CTLA-4 antibody 
therapy. Similar findings have been described with anti–PD-1 therapy in NSCLC.15 For 
melanoma and lung cancer, TMB may be driven by UV light exposure and chemically 
driven mechanisms rather than by MMR loss. 
Biliary tree cancers are generally characterized by a low TMB, with median TMB of 2.9 to 
5.7 mutations/Mb reported.16,17 The iCCA in our patient had a TMB of 17 mutations/Mb, 
which is impressive, given that Salem et al16 reported a high TMB (threshold of 15 
mutations/Mb) in only 2.9% of patients with biliary tract cancer. The high TMB was the 
motivation for recommending anti–PD-1 therapy to our patient. 
Use of TMB as a marker for response to ICI therapy is still evolving. A major challenge is 
defining a cutoff for low versus high TMB. Although a level of >20 mutations/Mb is 
reported in the literature for defining a high TMB, the threshold adopted in clinical practice 
is usually lower.13,18 In a recent examination of the efficacy of combination ipilimumab + 
nivolumab in NSCLC, a clinically relevant, less restrictive TMB threshold of 10 
mutations/Mb was used.19 It is also not clear whether this should be a dichotomous rather 
 
 
than a continuous classification, and some investigators have defined an intermediate 
TMB.13 Furthermore, a case could be made for individualizing TMB classification based 
on tumor histology, because a TMB of 10, which may be considered low in NSCLC, may 
have a different connotation in pancreatic ductal adenocarcinoma and biliary tree cancer 
or in other malignancies with generally low tumor mutations. Answering these questions 
will become important as TMB becomes more widely validated as a prognostic biomarker 
for immunotherapy. 
Interestingly, although next-generation sequencing showed that the CCA was 
microsatellite stable (MSS), paired tumor and normal tissue immunohistochemistry (IHC) 
showed loss of MLH1/PMS2 expression in the tumor. Subsequent PCR-based MSI 
analysis using the Promega kit did not show alterations in any microsatellite locus, 
consistent with MSS. This was in agreement with next-generation sequencing results. 
The discordance rate between IHC and PCR for detecting MSI is <5%, and the 
performance (and interpretation) of IHC is more prone to errors than PCR-based 
testing.20,21 Importantly, although testing for MSI and MMR proteins is standardized and 
validated in colorectal and endometrial cancer, this is not the case in other Lynch 
syndrome–associated malignancies. For example, a review of 834 cases of ovarian 
cancer reported a concordance rate of only 68% between IHC- and PCR-based 
testing.22 This suggests that data for colorectal cancer cannot be extrapolated to other 
malignancies. In our patient, the agreement between PCR and next-generation 
sequencing increased our confidence that he had MSS disease, although it can be argued 
that MLH1/PMS2 loss by IHC is sufficient to identify MMR deficiency. Nevertheless, we 
did not perform any tests to directly assess MLH1 promoter hypermethylation. 
Investigators have reported MLH1 promoter hypermethylation in approximately 20% of 
MSS colorectal cancer cases, although in this series, it did not translate to loss of MLH1 
expression.23 Furthermore, in a cohort of patients with ovarian cancer, approximately 
10% (3 of 28 samples) of MSS (PCR-based assay) samples had MLH1 promoter 
hypermethylation.24 We therefore concede that high TMB may be related to MMR 
deficiency secondary to MLH1 alteration. Indeed, in the absence of a high tumor 




Another interesting hypothesis regarding our patient is whether genomic instability 
caused by the BRCA mutation (independent of a high TMB) may have contributed to 
prolonged survival and the durable response to immunotherapy. BRCA mutations are 
rare in CCA,25,26 and the BRCA2 R3052Q mutation detected in our patient was 
considered a variant of unknown significance. The role of BRCA mutations specifically 
and homologous recombination deficiency (HRD; marker of genomic instability) in 
determining response to immunotherapy has not been clearly defined. A few reports link 
HRD to a high TMB,27,28 but data are still early. Because HRD has been explored as a 
biomarker for the use of PARP inhibitors and may become important for immunotherapy, 
it is important to develop an assay that would be applicable across malignancies. The 
HRD assay that is currently available was developed for breast and ovarian cancers. 
CONCLUSIONS 
This report presents a patient with chemotherapy-resistant iCCA and a high TMB who 
experienced prolonged disease control with immunotherapy. This impressive response 
highlights the usefulness of tumor genome profile testing as a tool for guiding therapy. 
These findings also strengthen the case for exploring high TMB as a tumor agnostic 
biomarker of response to immune therapy. We highlight a potential challenge with the 
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